CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients

M. Matsushita, K. Ozawa, T. Suzuki, M. Nakamura, N. Nakano, S. Kanchi, D. Ichikawa, E. Matsuki, M. Sakurai, D. Karigane, H. Kasahara, N. Tsukamoto, T. Shimizu, T. Mori, H. Nakajima, S. Okamoto, Y. Kawakami, Y. Hattori

研究成果: Article査読

11 被引用数 (Scopus)


Although the introduction of tyrosine kinase inhibitors (TKIs) has improved overall survival of patients with chronic myeloid leukemia (CML), about half of the patients eventually relapse after cessation of TKIs. In contrast, the remainder of the patients maintain molecular remission without TKIs, indicating that the patients' immune system could control proliferation of TKI-resistant leukemic stem cells (LSCs). However, the precise mechanism of immunity against CML-LSCs is not fully understood. We have identified a novel immune target, CXorf48, expressed in LSCs of CML patients. Cytotoxic T cells (CTLs) induced by the epitope peptide derived from CXorf48 recognized CD34 + CD38 â' cells obtained from the bone marrow of CML patients. We detected CXorf48-specific CTLs in the peripheral blood mononuclear cells from CML patients who have discontinued imatinib after maintaining complete molecular remission for more than 2 years. Significantly, the relapse rate of CXorf48-specific CTL-negative patients was 63.6%, compared to 0% in CXorf48-specific CTL-positive patients. These results indicate that CXorf48 could be a promising therapeutic target of LSCs for immunotherapy to obtain durable treatment-free remission in CML patients.

ジャーナルBlood cancer journal
出版ステータスPublished - 2017 9月 1

ASJC Scopus subject areas

  • 血液学
  • 腫瘍学


「CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。